[Psychotropic Medication and Operating Automobiles and Machinery].

Koji Matsuo
{"title":"[Psychotropic Medication and Operating Automobiles and Machinery].","authors":"Koji Matsuo","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Beginning in March 2013 and following again in May of the same year, warnings on the potential for medication-related impairment during the operation of motor vehicles were issued by the Ministry of Internal Affairs and Communication as well as the Ministry of Health, Labour, and Welfare. These notices have proven to be confusing for staff at psychiatric departments and pharmacies alike, as many widely prescribed psychotropic medications were included on the list. In response.to this issue, here I reviewed the aforementioned proscriptions as well as equivalent pronouncements from other countries and provided a brief overview on the subject from the point of view of pharmaceutical companies and regulatory agencies. The results showed that drug safety regulations in Japan were significantly more restrictive than the other countries surveyed for driving automobiles and operating machinery, and that the tone of the language used differed greatly from country to country. Additionally, observation of the current situation in the EU specifically reveals that, compared to Japan, the issue is being confronted much more proactively. Moving forward, it is recommended that Japan also, through the combined effort of regulatory agencies, academia, medical facilities, pharmaceutical companies and patients and their families, make greater efforts to adopt standards that assure traffic safety for the general public at large while concurrently respecting patients' right to freedom of movement and autonomy, even when receiving medical treatment.</p>","PeriodicalId":21638,"journal":{"name":"Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica","volume":"118 3","pages":"159-168"},"PeriodicalIF":0.0000,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Beginning in March 2013 and following again in May of the same year, warnings on the potential for medication-related impairment during the operation of motor vehicles were issued by the Ministry of Internal Affairs and Communication as well as the Ministry of Health, Labour, and Welfare. These notices have proven to be confusing for staff at psychiatric departments and pharmacies alike, as many widely prescribed psychotropic medications were included on the list. In response.to this issue, here I reviewed the aforementioned proscriptions as well as equivalent pronouncements from other countries and provided a brief overview on the subject from the point of view of pharmaceutical companies and regulatory agencies. The results showed that drug safety regulations in Japan were significantly more restrictive than the other countries surveyed for driving automobiles and operating machinery, and that the tone of the language used differed greatly from country to country. Additionally, observation of the current situation in the EU specifically reveals that, compared to Japan, the issue is being confronted much more proactively. Moving forward, it is recommended that Japan also, through the combined effort of regulatory agencies, academia, medical facilities, pharmaceutical companies and patients and their families, make greater efforts to adopt standards that assure traffic safety for the general public at large while concurrently respecting patients' right to freedom of movement and autonomy, even when receiving medical treatment.

[精神药物治疗和汽车机械操作]。
从2013年3月开始到同年5月,内务和通信省以及卫生、劳动和福利省发布了关于机动车辆运行过程中与药物有关的潜在损害的警告。事实证明,这些通知让精神科和药房的工作人员感到困惑,因为许多广泛使用的精神药物都包括在清单上。作为回应。针对这一问题,我在这里回顾了上述禁令以及其他国家的类似声明,并从制药公司和监管机构的角度简要概述了这一问题。结果显示,在驾驶汽车和操作机械方面,日本的药品安全法规比其他接受调查的国家严格得多,使用的语言语调也因国家而异。此外,对欧盟当前形势的观察表明,与日本相比,欧盟正更加积极地应对这一问题。展望未来,建议日本还通过监管机构、学术界、医疗设施、制药公司和患者及其家属的共同努力,作出更大努力,采用标准,确保广大公众的交通安全,同时尊重患者的行动自由和自主权,即使在接受治疗时也是如此。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信